Top

Cancer Immunology, Immunotherapy

Published in:

01-10-1998 | ORIGINAL ARTICLE

Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen

Authors: Ali Samanci, Qing Yi, Jan Fagerberg, Karin Strigård, Gale Smith, Ulla Rudén, Britta Wahren, Håkan Mellstedt

Published in: Cancer Immunology, Immunotherapy | Issue 3/1998

Title: Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen
Authors: Ali Samanci
Qing Yi
Jan Fagerberg
Karin Strigård
Gale Smith
Ulla Rudén
Britta Wahren
Håkan Mellstedt
Publication date: 01-10-1998
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 3/1998
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s002620050513

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 3/1998

Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cells

Activation of EGF receptor family members suppresses the cytotoxic effects of tumor necrosis factor-α

Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2

Adjuvant treatment of breast cancer: A pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha

Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell Malignancy

The effect of recombinant human granulocyte/macrophage-colony-stimulating factor (rHu GM-CSF) and rHu G-CSF administration on neutrophil chemiluminescence assay in patients following cyclic chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer